What is Cadence Biomedical?
Cadence Biomedical is a specialized medical device manufacturer focused on the development of Kickstart, a proprietary neurorehabilitation tool designed to restore mobility. The device functions as a lightweight, wearable system that provides stability and mechanical assistance to individuals with neurological conditions. By facilitating natural walking patterns, the technology serves both professional clinical environments and home-based recovery programs. Its recognition by Medicare and private insurance providers highlights its clinical efficacy and market viability, positioning the company as a critical player in the intersection of physical therapy and assistive robotics.
How much funding has Cadence Biomedical raised?
Cadence Biomedical has raised a total of $3.3M across 3 funding rounds:
Series A
$1.1M
Private Equity
$959K
Series B
$1.2M
Series A (2012): $1.1M with participation from Keiretsu Forum, Alliance of Angels, Tech Coast Angels, Sand Hill Angels, and HealthTech Capital
Private Equity (2015): $959K, investors not publicly disclosed
Series B (2015): $1.2M supported by HealthTech Capital and Frontier Angels
Key Investors in Cadence Biomedical
HealthTech Capital
A Silicon Valley-based investment organization that specializes in healthtech and digital health startups, providing both capital and strategic mentoring to early-stage ventures.
Frontier Angels
A Montana-based network of over 100 accredited angel investors focused on accelerating the growth of high-potential technology startups through seed and Series A financing.
Keiretsu Forum
A global investment community of accredited private equity angel investors, venture capitalists, and corporate/institutional investors focused on early-stage opportunities.
What's next for Cadence Biomedical?
With the recent influx of capital, Cadence Biomedical is poised to accelerate its market penetration and expand its clinical footprint. The strategic focus will likely shift toward optimizing supply chain logistics and broadening insurance coverage to ensure the Kickstart device reaches a wider patient demographic. Furthermore, the company is expected to invest in longitudinal data collection to further validate the long-term recovery outcomes associated with its technology. As the firm matures, it will likely explore additional indications for its gait-assistance platform, potentially diversifying its product pipeline to address a broader spectrum of mobility-related disabilities.
See full Cadence Biomedical company page
